Intervacc has recently received its first patent in the United States. "The U.S. is a key market for Intervacc and it is very gratifying that our first patent has been granted on this large market," says Chairman Rune Bergman.

Intervacc AB (publ) is a Swedish life science company specializing in the development of vaccines. The company has successfully completed a rights issue that adds 26 million SEK before customary transaction costs.